Estimating hospital inpatient cost-savings with sucroferric oxyhydroxide in patients on chronic hemodialysis in five European countries: a cost analysis

References

• Hutchison AJ. Oral phosphate binders. Kidney Int. 2009;75(9):906–914.
   PubMed Web of Science ®Google Scholar
• Locatelli F, Del Vecchio L, Violo L, et al. Phosphate binders for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis: a comparison of safety profiles. Expert Opin Drug Saf. 2014;13(5):551–561.
   PubMed Web of Science ®Google Scholar
• National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003;42(4 Suppl 3):S1–S201.
   PubMed Web of Science ®Google Scholar
• Fernandez-Martin JL, Carrero JJ, Benedik M, et al. COSMOS: the dialysis scenario of CKD-MBD in Europe. Nephrol Dial Transplant. 2013;28(7):1922–1935.
   PubMed Web of Science ®Google Scholar
• Block GA, Hulbert-Shearon TE, Levin NW, et al. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis. 1998;31(4):607–617.
   PubMed Web of Science ®Google Scholar
• Block GA, Klassen PS, Lazarus JM, et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol. 2004;15(8):2208–2218.
   PubMed Web of Science ®Google Scholar
• Ganesh SK, Stack AG, Levin NW, et al. Association of elevated serum PO(4), Ca x PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol. 2001;12(10):2131–2138.
   PubMed Web of Science ®Google Scholar
• Slinin Y, Foley RN, Collins AJ. Calcium, phosphorus, parathyroid hormone, and cardiovascular disease in hemodialysis patients: the USRDS waves 1, 3, and 4 study. J Am Soc Nephrol. 2005;16(6):1788–1793. Jun
   PubMed Web of Science ®Google Scholar
• Saran R, Bragg-Gresham JL, Rayner HC, et al. Nonadherence in hemodialysis: associations with mortality, hospitalization, and practice patterns in the DOPPS. Kidney Int. 2003;64(1):254–262.
   PubMed Web of Science ®Google Scholar
• Barreto FC, Barreto DV, Massy ZA, et al. Strategies for phosphate control in patients with CKD. Kidney Int Rep. 2019;4(8):1043–1056.
   PubMed Web of Science ®Google Scholar
• Cannata-Andia JB, Martin KJ. The challenge of controlling phosphorus in chronic kidney disease. Nephrol Dial Transplant. 2016;31(4):541–547.
   PubMed Web of Science ®Google Scholar
• Vervloet MG, van Ballegooijen AJ. Prevention and treatment of hyperphosphatemia in chronic kidney disease. Kidney Int. 2018;93(5):1060–1072.
   PubMed Web of Science ®Google Scholar
• Achinger SG, Ayus JC. The role of daily dialysis in the control of hyperphosphatemia. Kidney Int. 2005;67:S28–S32.
   Web of Science ®Google Scholar
• Hutchison AJ, Smith CP, Brenchley PE. Pharmacology, efficacy and safety of oral phosphate binders. Nat Rev Nephrol. 2011;7(10):578–589.
   PubMed Web of Science ®Google Scholar
• Isakova T, Nickolas TL, Denburg M, et al. KDOQI US commentary on the 2017 KDIGO clinical practice guideline update for the diagnosis, evaluation, prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Am J Kidney Dis. 2017;70(6):737–751.
   PubMed Web of Science ®Google Scholar
• Tonelli M, Pannu N, Manns B. Oral phosphate binders in patients with kidney failure. N Engl J Med. 2010;362(14):1312–1324.
   PubMed Web of Science ®Google Scholar
• Floege J. Phosphate binders in chronic kidney disease: an updated narrative review of recent data. J Nephrol. 2020;33(3):497–508.
   PubMed Web of Science ®Google Scholar
• Frazão JM, Frazão JM, Adragão T. Non-calcium-containing phosphate binders: comparing efficacy, safety, and other clinical effects. Nephron Clin Pract. 2012;120(2):c108–c119.
   PubMedGoogle Scholar
• Chiu YW, Teitelbaum I, Misra M, et al. Pill burden, adherence, hyperphosphatemia, and quality of life in maintenance dialysis patients. Clin J Am Soc Nephrol. 2009;4(6):1089–1096.
   PubMed Web of Science ®Google Scholar
• Fissell RB, Karaboyas A, Bieber BA, et al. Phosphate binder pill burden, patient-reported non-adherence, and mineral bone disorder markers: findings from the DOPPS. Hemodial Int. 2016;20(1):38–49.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Velphoro® summary of product characteristics; 2019. Available from: https://www.ema.europa.eu/en/documents/product-information/velphoro-epar-product-information_en.pdf
   Google Scholar
• U.S. Food and Drug Administration. Velphoro® prescibing information; 2020. Available from: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=237da26c-f38c-4faa-93ad-735e71c9d0c1.
   Google Scholar
• Wilhelm M, Gaillard S, Rakov V, et al. The iron-based phosphate binder PA21 has potent phosphate binding capacity and minimal iron release across a physiological pH range in vitro. Clin Nephrol. 2014;81(4):251–258.
   PubMed Web of Science ®Google Scholar
• Floege J, Covic AC, Ketteler M, et al. A phase III study of the efficacy and safety of a novel iron-based phosphate binder in dialysis patients. Kidney Int. 2014;86(3):638–647.
   PubMed Web of Science ®Google Scholar
• Floege J, Covic AC, Ketteler M, et al. One-year efficacy and safety of the iron-based phosphate binder sucroferric oxyhydroxide in patients on peritoneal dialysis. Nephrol Dial Transplant. 2017;32(11):1918–1926.
   PubMed Web of Science ®Google Scholar
• Coyne DW, Ficociello LH, Parameswaran V, et al. Real-world effectiveness of sucroferric oxyhydroxide in patients on chronic hemodialysis: a retrospective analysis of pharmacy data. Clin Nephrol. 2017;88(08):59–67.
   PubMed Web of Science ®Google Scholar
• Kendrick J, Parameswaran V, Ficociello LH, et al. One-year historical cohort study of the phosphate binder sucroferric oxyhydroxide in patients on maintenance hemodialysis. J Renal Nutr. 2019;29(5):428–437.
   PubMed Web of Science ®Google Scholar
• Coyne DW, Ficociello LH, Parameswaran V, et al. Sucroferric oxyhydroxide in maintenance hemodialysis: a retrospective, comparative cohort study. Kidney Med. 2020;2(3):307–316.
   PubMedGoogle Scholar
• European Commission. Harmonized index of consumers prices. Available from: https://ec.europa.eu/eurostat/web/hicp/data/database.
   Google Scholar
• Bank of England. Daily spot exchange rates against Sterling. Available from: https://www.bankofengland.co.uk/boeapps/database/Rates.asp?Travel=NIxASx&into=GBP&mc_phishing_protection_id=28632-c5e3vglse2ip65fhtgeg.
   Google Scholar
• Eurostat. Purchasing power parities (PPPs), price level indices and real expenditures for ESA 2010 aggregates 2021. Available from: https://ec.europa.eu/eurostat/databrowser/view/prc_ppp_ind/default/table?lang=en.
   Google Scholar
• HAS. Évaluation médico-économique des stratégies de prise en charge de l’insuffisance rénale chronique terminale en France 2014. Available from: https://www.has-sante.fr/portail/upload/docs/application/pdf/2014-11/argumentaire_irct_vf_2014-11-06_19-21-13_876.pdf#page=104&zoom=100,0,328.
   Google Scholar
• Gandjour A, Armsen W, Wehmeyer W, et al. Costs of patients with chronic kidney disease in Germany. PLoS One. 2020;15(4):e0231375.
   PubMed Web of Science ®Google Scholar
• Roggeri P, Roggeri A, Salomone M. Chronic kidney disease: Evolution of healthcare costs and resource consumption from predialysis to dialysis in Piedmont region, Italy. Advances in Nephrology. 2014;2014:1–6.
   Google Scholar
• MSCBS. NORMA ESTATAL APR-GRD Hospitales de agudos - BASAL 2017. [cited 20 February 2020]. Available from: https://www.mscbs.gob.es/estadEstudios/estadisticas/cmbd.htm.
   Google Scholar
• Kent S, Schlackow I, Lozano-Kühne J, et al. What is the impact of chronic kidney disease stage and cardiovascular disease on the annual cost of hospital care in moderate-to-severe kidney disease? BMC Nephrol. 2015;16:65.
   PubMed Web of Science ®Google Scholar
• Fernandez-Martin JL, Martinez-Camblor P, Dionisi MP, et al. Improvement of mineral and bone metabolism markers is associated with better survival in haemodialysis patients: the COSMOS study. Nephrol Dial Transplant. 2015;30(9):1542–1551. Sep
   PubMed Web of Science ®Google Scholar
• Young EW, Akiba T, Albert JM, et al. Magnitude and impact of abnormal mineral metabolism in hemodialysis patients in the dialysis outcomes and practice patterns study (DOPPS). Am J Kidney Dis. 2004;44(5 Suppl 2):34–38.
   PubMed Web of Science ®Google Scholar
• Coladonato JA. Control of hyperphosphatemia among patients with ESRD. J Am Soc Nephrol. 2005;16 Suppl 2:S107–S114.
   PubMed Web of Science ®Google Scholar
• Cernaro V, Santoro D, Lacquaniti A, et al. Phosphate binders for the treatment of chronic kidney disease: role of iron oxyhydroxide. Int J Nephrol Renovasc Dis. 2016;9:11–19.
   PubMed Web of Science ®Google Scholar
• Floege J. Phosphate binders in chronic kidney disease: a systematic review of recent data. J Nephrol. 2016;29(3):329–340.
   PubMed Web of Science ®Google Scholar
• Mason MA, Shepler BM. Evaluation of morbidity and mortality data related to cardiovascular calcification from calcium-containing phosphate binder use in patients undergoing hemodialysis. Pharmacotherapy. 2010;30(7):741–748.
   PubMed Web of Science ®Google Scholar
• Scialla JJ, Wolf M. Roles of phosphate and fibroblast growth factor 23 in cardiovascular disease. Nat Rev Nephrol. 2014;10(5):268–278.
   PubMed Web of Science ®Google Scholar
• St Peter WL, Wazny LD, Weinhandl E, et al. Erratum to: a review of phosphate binders in chronic kidney disease: incremental progress or just higher costs? Drugs. 2017;77(14):1611.
   PubMed Web of Science ®Google Scholar
• Scialla JJ, Kendrick J, Uribarri J, et al. State-of-the-art management of hyperphosphatemia in patients with CKD: an NKF-KDOQI controversies perspective. Am J Kidney Dis. 2021;77(1):132–141.
   PubMed Web of Science ®Google Scholar
• Wang S, Alfieri T, Ramakrishnan K, et al. Serum phosphorus levels and pill burden are inversely associated with adherence in patients on hemodialysis. Nephrol Dial Transplant. 2014;29(11):2092–2099.
   PubMed Web of Science ®Google Scholar
• Lindemann K, Ajala C, Rosen MM, et al. An observational analysis of hospital admissions and total member costs associated with the use of various phosphate binders used in dialysis patients included in ESRD seamless care organizations. J Am Soc Nephrol. 2020;31. Abstract no PO0371.
   Google Scholar
• Negri AL. Phosphate binders, cardiovascular calcifications and mortality: do we need another survival study with sevelamer? J Nephrol. 2010;23(6):653–657.
   PubMed Web of Science ®Google Scholar
• Gutzwiller FS, Pfeil AM, Ademi Z, et al. Cost effectiveness of sucroferric oxyhydroxide compared with sevelamer carbonate in the treatment of hyperphosphataemia in patients receiving dialysis, from the perspective of the national health service in Scotland. Pharmacoeconomics. 2015;33(12):1311–1324.
   PubMed Web of Science ®Google Scholar
• (SMC) SMC. sucroferric oxyhydroxide 500mg chewable tablets (Velphoro ®) SMC No. (1035/15) 2015.
   Google Scholar